Regulatory french replicates [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2009-09-30 18:48 (6099 d 10:16 ago) – Posting: # 4279
Views: 5,068

Dear Yung-jin,

❝ Guess many other colleagues are looking for the answers of your QUESTION now. I don't know if I can really help here. But allow me to try first. :-)


Thanx.

❝ To calculate intra-individual variabilities and means seems not a problem for the guy like you.


Of course not :-P . One part of the output of the Proc MIXED code contains the intra-subject variabilities for Test and Reference and the between-subject variability also. They have therefore what they request.
But it seems they do not belief in the results of the REML estimates from that Proc MIXED
That's where my confusion comes from. And means make no sense within the category if intra-subject variance.

❝ Or see Hauschke D., et al., "Bioequivalence Studies in Drug Development - Methods and Applications", 2007, pp. 258-9.


Cannot find anything about intra-subject variabilities on that pages.

❝ [...] [BTW, where to get it? Is this drug2-replicate program (SAS macros) freely available?]



Sorry. But its the property of the company I am working in.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
106 visitors (0 registered, 106 guests [including 25 identified bots]).
Forum time: 05:05 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5